email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
541 - 555
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
Tigermed Expands Footprint and Services by Acquiring Marti Farm, a Croatian CRO
$5.00
Available
Aprinoia, a Neurodegenerative Company, to be Acquired by $280 Million SPAC
$5.00
Available
Nanjing IASO Bio Raises $75 Million to Develop/Commercialize CAR-T Assets
$5.00
Available
GenScript ProBio -- a mAb, Cell & Gene Therapy CDMO -- Raises $224 Million
$5.00
Available
Henlius anti-PD-1 Approved to Launch in China for Small Cell Lung Cancer
$5.00
Available
CARsgen Signs $181 Million Deal to Commercialize CAR-T in China with Huadong
$5.00
Available
Harbour Biomed to Start US Trials of Novel B7H7 Immunoncology Asset
$5.00
Available
Bio4t2 Starts China Trial of BT-001 Antigen CAR-T for Solid Tumor Cancers
$5.00
Available
Visen Pharma Completes Phase III Trial of Therapy for Rare Thyroid Disease
$5.00
Available
Evopoint Options-Out Rights for Pre-clinical Solid Tumor ADC to AmMax
$5.00
Available
Takeda Approved to Launch Targeted Drug for NSCLC with Mutations in China
$5.00
Available
Chengdu Qitan Raises $101 Million for Nanopore Sequencing Devices
$5.00
Available
Dizal’s NDA Filing for NSCLC Therapy Accepted for Review in China
$5.00
Available
Innovent Starts China Phase III Trial for Dual Agonist Diabetes Therapy
$5.00
Available
Immune-Onc Adds $25 Million to B Round for Novel Myeloid Checkpoint Inhibitors
$5.00
Available